clinical trial · NCT04533022
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Idiopathic Pulmonary FibrosisC21
brief summary
This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.
started
Nov 13, 2020
primary completion
Mar 30, 2024
completion
Mar 30, 2024
last updated
May 23, 2025
official title
A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol